Strong Phoxim Solution Veterinary Grade API is a concentrated organothiophosphate liquid intended for further manufacture into tablets, injections, capsules, powders, granules, premix, and solutions. The active moiety is phoxim, CAS 14816-18-3, molecular formula C₁₂H₁₅N₂O₃PS, relative molecular mass 298.30. The solution is released as a non-sterile active pharmaceutical ingredient with assay expressed as percent w/w of label claim; each batch is accompanied by a certificate of analysis recording identity, assay, water, residual solvents, related substances, and specified impurity data. The product commercial designation includes the word “Strong,” which refers to the concentrated liquid presentation rather than to an independent potency claim. The model specification is defined by the active strength, solvent system, and intended dosage-route compatibility; when supply-chain coding is required, the manufacturer’s model code appears on the package label and certificate of analysis.

The supplied solution is a clear amber to reddish-brown liquid with characteristic solvent odour. Published physicochemical data for phoxim indicate a log Kow of approximately 3.38 and aqueous solubility near 1.5 mg/L at 20 °C. These properties explain the solvent-based liquid presentation, the preference for hydrophobic interaction during manufacture, and the limited removal of the active substance from equipment surfaces by water alone. Downstream manufacturing routes include wet granulation for tablets and granules, adsorption onto precipitated silica or attapulgite for powders and premixes, dilution into non-aqueous pour-on solutions, and, where registered, incorporation into non-aqueous injectable vehicles after appropriate filtration. The solution is not intended for direct administration without formulation; dilution into a finished veterinary medicinal product must follow species-specific dose, residue, and withdrawal-period requirements.

In comparison to agricultural organophosphate concentrates, the veterinary API is differentiated by impurity-control and residual-solvent limits. Technical-grade phoxim may contain sediment, water, and reaction by-products that are not suitable for a veterinary active ingredient. The veterinary solution is clarified and controlled under good manufacturing practice. This is particularly relevant when the liquid is adsorbed onto high-surface-area carriers, because polar impurities can occupy binding sites on silica or silicate carriers and change the release behaviour of subsequent tablets or granules.

What Limits Metering Precision in Cold-Feed Premix Lines?

Concentrated phoxim solutions show temperature-dependent viscosity. When line temperature is not controlled, the flow rate through metering pumps changes and assay in the premix drifts. Production lines therefore use insulated feed vessels, gear pumps with recirculation loops, and mass-flow meters rather than simple volumetric pumps calibrated only at a single temperature. The solution is warmed to 35–45 °C before the injection nozzle to maintain consistent atomization and to prevent intermittent dripping that creates localized high-concentration pockets. In batch records, density differences between solvent lots change the volumetric assay when addition is not compensated by mass; Coriolis mass-flow metering reduces this source of variability in large premix batches.

Spray and adsorption operations are governed by carrier oil absorption. Overloading creates free liquid that can segregate during subsequent blending; underloading leaves the active substance unevenly distributed. The practical endpoint is determined by carrier wetness and flow properties, not solely by mixing time. Carriers with elevated iron content are avoided because transition metals accelerate oxidative decomposition of the phosphorothioate ester, which can raise the oxon-related impurity fraction during storage. For granulated premixes, the solution is introduced after dry powders have been premixed. Direct addition into a high-shear mixer without premixing can cause localized overwetting and resinous lumps on the chopper blades. Transfer of the wet mass to a fluid-bed dryer is preferred over static tray drying when bed depth is high because residual solvent removal is more reproducible, provided that inlet air temperature is held below the formulation-specific thermal limit.

For powder and granule premixes, a stepwise dilution is required. The solution is first blended into a portion of carrier to make a concentrated pre-blend; the pre-blend is then mixed with the remaining carrier in a ribbon blender or plow mixer. Mixing time must be validated because phoxim adsorbed onto porous carrier can show slow migration into the surrounding diluent. Overmixing can generate fines and increase exposed surface area, which may reduce chemical stability under humid storage.

Residual water in the carrier is a stronger predictor of long-term assay loss than initial total impurities. Carriers with a loss on drying above 1.5% w/w should be pre-dried before liquid loading. Pre-drying at 80–100 °C for 2–4 h is typical for precipitated silica, but the exact conditions must not degrade the carrier structure or reduce oil absorption capacity.

For tablets and capsules, a pre-adsorbed powder intermediate is prepared by blending the liquid with silicon dioxide or a suitable silicate carrier. Neat liquid added directly to a V-blender or bin blender produces poor uniformity because the solution binds to the first contact surfaces. The pre-adsorbed intermediate is then mixed with lactose monohydrate, croscarmellose sodium, and magnesium stearate; final blend moisture and residual solvent are controlled before compression or encapsulation to avoid gelatin shell softening and punch filming. Compression parameters are formulation-specific and are established by content uniformity and dissolution testing rather than transferred directly from another organophosphate product.

Hard gelatin capsules require the pre-adsorbed intermediate to have low residual solvent because solvent migration to the shell can soften the capsule body. Capsule filling on dosator machines is more sensitive to blend density than tamping-pin machines; the blend bulk density is therefore specified and monitored with a tapped-density method such as Ph. Eur. 2.2.42. This is especially important when the product is filled on high-speed lines at more than 60,000 capsules per hour.

For injectable manufacture, the non-aqueous solvent system requires evaluation for compatibility with plunger-stopper elastomers, sterilizing filter membranes, and the final container. PTFE or polyvinylidene fluoride membranes are generally more suitable than nylon because of lower extractables. Terminal sterilization by autoclave at 121 °C for 15 min is not automatically suitable; the thermal stability of the formulation must be demonstrated because acidic degradation products can shift pH. When stability data do not support terminal sterilization, filtration through 0.22 µm membranes is used under aseptic conditions, subject to regulatory acceptance. Published data for this exact solution in terminal sterilization cycles are limited, so formulation-specific filter compatibility and extractables studies are required. Because the API is non-sterile, the receiving site must either filter the formulation through a sterilizing-grade membrane or terminally sterilize; the final sterile product must meet sterility, pyrogen, particulate, and dose-uniformity requirements according to the regional pharmacopoeia.

For non-aqueous injectable solutions, water content is critical because phoxim hydrolyses rapidly when a water-rich phase separates. The solvent system should therefore be dried before compounding, and headspace moisture in the formulation vessel should be excluded by nitrogen overlay. Filter compatibility studies are performed with the actual drug concentration because the solvent system can extract plasticizers from some filter cartridges.

Assay, Related-Substance, and Residual-Solvent Limits in the API Release Profile

The active-substance manufacturer and the receiving site use a stability-indicating HPLC method validated for linearity, precision, accuracy, specificity, and robustness in accordance with VICH GL1. Residual solvents are determined by headspace gas chromatography based on VICH GL18. A representative release profile for a concentrated veterinary API solution is presented in Table 1.

Batch-specific numerical results may be tighter than the listed limits; the certificate of analysis is the controlling document. The microbial limits shown apply to the non-sterile API and are not sufficient for parenteral release. For solution presentations, a visible-particulate check is also included after the clarification step; the solution is not claimed to be sterile and is not intended for direct injection.

Stability is sensitive to water and alkaline pH. Phoxim hydrolyses above pH 8; packages should be closed under nitrogen and stored below 25 °C in dry conditions. After first opening, nitrogen blanketing or a desiccant breather on the drum closure reduces moisture ingress. Repeated partial-container withdrawal can increase headspace moisture and should be managed by use of smaller containers when frequent opening is expected.

When Phoxim Solution Replaces Technical-Grade Insecticide in GMP Dosage Manufacture

Replacement of technical-grade phoxim with the veterinary API solution changes impurity profile, drying behaviour, and cleaning burden. Technical-grade material may contain non-volatile residues that act as plasticizers in tablet matrices; the veterinary solution has a controlled residue-on-ignition and a narrower specified solvent range. Process transfers therefore require revalidation of granulation solvent removal because different solvent residues partition differently into carrier pores. A comparative overview is given in Table 2.

In transfer lines, the solution is recirculated through a low-shear pump until density or refractive index measurements show homogeneity. Sampling from the recirculation loop is preferred over top-sampling because storage can create concentration gradients. Cleaning validation uses swab recovery because phoxim is lipophilic; aqueous rinses alone are generally insufficient to meet visual-clean criteria on stainless steel. Alkaline detergent solutions improve removal from baffles and dead legs, but the cleaning agent must be rinsed thoroughly to avoid pH residues. In multi-product plants, cross-contamination criteria are calculated from the lowest acceptable daily exposure of phoxim and the maximum daily dose of the next product.

Formulators replacing solid phoxim powder reduce dust exposure but introduce solvent-handling requirements. The solution is stored separately from oxidising agents, strong acids, and strong alkalis. Chlorinated solvents and peroxide-forming compounds are avoided unless specific compatibility data are available. Contact with copper, zinc, or iron is avoided because catalytic metal surfaces accelerate degradation of the phosphorothioate ester.

Phoxim acts after metabolic activation to the corresponding oxon, which inhibits acetylcholinesterase. This mechanism distinguishes it from direct-acting carbamates, although cross-resistance with other organophosphates can occur through esterase-based mechanisms. In integrated parasite-control programmes, rotation with compounds having different target-site chemistry is evaluated by field efficacy studies rather than inferred from laboratory enzyme assays alone.

The finished product must comply with regional maximum residue limits and withdrawal periods for treated animals. The API manufacturer’s certificate of analysis does not substitute for a marketing-authorization holder’s residue file. No administration to food-producing species is permitted without a registered formulation and a defined withdrawal period. Liquid finished solutions intended for prolonged stability should use containers selected for low sorption and low oxygen transmission; high-density polyethylene and polyethylene terephthalate are assessed on a case-specific basis because the active substance can sorb into some polyolefin surfaces.